In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arrowhead Pharmaceuticals, Inc.

http://arrowheadpharma.com/

Latest From Arrowhead Pharmaceuticals, Inc.

GSK Takes Over J&J/Arrowhead Hep B Candidate For Combo Development

Deal Snapshot: Seeking to develop a combination regimen for chronic hepatitis B, GSK acquires rights to J&J/Arrowhead’s siRNA candidate JNJ-3839 to pair with its antisense candidate bepiroversen.

Deals Business Strategies

Ionis Closer To First Wholly-Owned Drug Launch With Olezarsen Phase III Success

Ionis will seek US and EU approvals to treat familial chylomicronemia syndrome in the first half of 2024. Phase III data in the larger severe hypertriglyceridemia indication are due in late 2024 or early 2025.

Clinical Trials Rare Diseases

Beam Picks Crowded AAT Field To Prove Its In Vivo Gene Editing

With its first US study for a base-edited CAR-T therapy now back on track, Beam Therapeutics is gearing up to begin studies of its first in vivo candidate, BEAM-302, next year in AAT.

Liver & Hepatic Metabolic Disorders

Asthma And RSV Will Be Hot Topics At ERS 2023

Elsewhere at the European Respiratory Society meeting, Bristol Myers Squibb will hope that its LPA1 antagonist can add a hit in progressive pulmonary fibrosis to the success it has already posted in the idiopathic form of the disease. 

Clinical Trials Respiratory
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Other Names / Subsidiaries
    • Ablaris Therapeutics, Inc.
    • Alvos Therapeutics, Inc. (formerly Mercator Therapeutics, Inc.)
    • Arrowhead Research Corporation
    • Calando Pharmaceuticals, Inc.
    • Unidym
UsernamePublicRestriction

Register